0 followers
RT @JAMA_current: In patients with moderately to severely active ulcerative colitis, risankizumab improved the rates of clinical remission…
RT @JAMA_current: In patients with moderately to severely active ulcerative colitis, risankizumab improved the rates of clinical remission…